KIMIA BIOSCIENCES LIMITED specializes in Pharmaceuticals within the Healthcare sector.
KIMIA BIOSCIENCES LIMITED, with Security Code 530313, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Date Begin | Date End | Net Sales | Net Profit | Total Income | Diluted EPS for continuing operation | Other Expenses | Other Income | Depreciation and amortisation expense | Profit (+)/ Loss (-) from Ordinary Activities before Tax |
|---|---|---|---|---|---|---|---|---|---|
| 2024-01-01 | 2024-03-31 | 303.02 | 17.95 | 306.05 | 0.38 | -33.39 | 3.03 | -8.18 | 23.06 |
| 2023-10-01 | 2023-12-31 | 261.45 | -19.52 | 267.21 | -0.41 | -37.89 | 5.76 | -8.19 | -26.01 |
| 2023-07-01 | 2023-09-30 | 242.00 | -24.42 | 248.38 | -0.52 | -38.35 | 6.37 | -8.23 | -32.67 |
| 2023-04-01 | 2023-06-30 | 242.30 | -27.11 | 243.55 | -0.57 | -39.90 | 1.25 | -8.32 | -36.22 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 2% |
| 3 Years: | -8% |
| TTM: | -18% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| TTM: | 36% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 17% |
| 3 Years: | 2% |
| 1 Year: | 37% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| TTM: | 0% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| 1 Year: | 0% |
Kimia Biosciences, a clinical-stage company developing novel treatments for inflammatory diseases, today announced positive topline results from a Phase 2a clinical trial evaluating the safety and efficacy of its lead product candidate, KB003, in patients with mild to moderate atopic dermatitis (AD).
Kimia Biosciences, a clinical-stage company developing novel treatments for inflammatory diseases, today announced that it will present new data from its Phase 2a clinical trial evaluating the safety and efficacy of its lead product candidate, KB003, in patients with mild to moderate atopic dermatitis (AD) at the 2023 Annual Meeting of the American Academy of Dermatology (AAD).
Kimia Biosciences, a clinical-stage company developing novel treatments for inflammatory diseases, today announced the closing of a $100 million Series C financing. The financing was led by new investor BVF Partners, with participation from existing investors RA Capital Management, Novo Holdings, and Sofinnova Partners.
